Developer docs
API playgroundTry for free, no card

Search company profiles

Gradient Bioconvergence

Full company profile

uuid000btp6

Namestring
Gradient Bioconvergence
Legal namestring
Gradiant Bioconvergence
Websiteurl
gradiantbio.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
patient-derived organoids, cancer drug discovery, AI target discovery, biomarker identification, organoid banking
Industry5 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Drug Discovery Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Drug Efficacy Evaluation Services
TypeProfessional Services
Description

Contract service providing drug efficacy evaluation using proprietary PDO platforms for pharmaceutical and biotech companies.

gradiantbio.com
2Biomarker Discovery Services
TypeProfessional Services
Description

AI-based biomarker discovery services for drug response prediction and patient stratification.

gradiantbio.com
3Target Discovery Services
TypeProfessional Services
Description

Novel anticancer target identification and validation services using PDO and AI platforms.

gradiantbio.com
4Licensing Royalties
TypeLicensing Royalties
Description

Technology licensing including decellularized scaffold patents and organoid culture technology to other biotech companies.

gradiantbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gradient Bioconvergence develops patient-derived organoids (PDOs) for cancer research and drug development. The company operates Asia's largest PDO banking system with approximately 1,000 organoid types paired with NGS genomic and clinical data, and combines this with proprietary AI algorithms to deliver drug efficacy evaluation, AI-driven anticancer target discovery, biomarker identification, and iPSC-derived organoid research services to pharmaceutical and biotech clients. It also advances its own drug candidate GBC-11004, a third-generation kinase inhibitor for EGFR-resistant NSCLC.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Drug development timeline reduction from over 10 years to 1-2 years with AI-based target discovery and PDO validation
+3 more records
Product overview1 text field

Gradient Bioconvergence operates a platform-plus-services model centered on patient-derived organoid (PDO) technology for drug discovery. The core offerings include PDO Banking (Asia's largest organoid bank with ~1,000 species paired with genomic and clinical data), the AI-Driven Target Discovery platform (combining PDO data with proprietary AI algorithms for target identification), iPSC-Derived Organoid Research services for brain disease modeling, Biomaterials for optimized organoid culture, an Immunotherapy Screening Platform using co-culture systems, and the proprietary drug candidate GBC-11004 (a kinase inhibitor for resistant NSCLC). The company licenses HUB organoid technology and employs CRISPR-based validation alongside its AI capabilities.

Product and service6 records
1PDO Banking
CategoryDrug Discovery Services
Description

Asia's largest Patient-Derived Organoid banking service with approximately 1,000 organoid species, each paired with patient clinical information and genomic data (NGS), used by pharmaceutical and biotech clients for drug efficacy evaluation and novel target discovery.

2AI-Driven Target Discovery
CategoryDrug Discovery Services
Description

AI-driven anticancer target discovery service that combines PDO big data with proprietary AI algorithms to identify high-confidence targets, validated through PDO-based CRISPR systems, for pharmaceutical and biotech partners.

3iPSC-Derived Organoid Research
CategoryDisease Modeling Services
Description

Customized research services using human induced pluripotent stem cell (hiPSC)-derived brain organoids for degenerative brain disease research, including co-culture models with microglia, for pharmaceutical and academic clients.

4Biomaterials
CategoryResearch Products
Description

Decellularized scaffold and culture materials optimized for organoid culture, enabling 3D culture and tissue environment simulation for organoid development, supplied to research and biotech customers.

5Immunotherapy Screening Platform
CategoryDrug Discovery Services
Description

Co-culture service combining patient-derived organoids with autologous immune cells for immunotherapy efficacy verification, enabling personalized cancer treatment screening for pharmaceutical and biotech clients.

6GBC-11004
CategoryDrug Candidate
Description

A proprietary novel 3rd generation kinase inhibitor drug candidate targeting EGFR inhibitor-resistant non-small cell lung cancer (NSCLC), being developed by Gradient Bioconvergence for global licensing partnerships.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

MOU with Chonnam National University Hwasun Hospital for anticancer drug response prediction and cancer organoid bank construction. The collaboration integrates patient-based clinical information with organoid analysis data to improve anticancer drug response prediction accuracy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

Strategic partnership with US Silicon Valley biotech company OmicInsight to integrate patient-derived organoid (PDO) platforms with spatial omics analysis technology for precision medicine research. The collaboration aims to enable deeper insight into tissue architecture, disease progression, and therapeutic response for drug discovery, precision medicine, and regenerative medicine.

3Dong-A ST
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-26
Description

Joint research agreement with Korean pharmaceutical company Dong-A ST for AI-based new drug development targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders. Leverages organoid analysis, genomic big data, and automated drug discovery platforms to reduce development timelines from over 10 years to 1-2 years and cut costs by 15-30 percent.

koreabiomed.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint research contract for PDO co-culture and immunotherapy screening platform development with Yonsei Medical Center. Expanding collaboration from lung cancer to pancreatic cancer and ovarian cancer organoid research.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

MOU with BCChem for first-in-class anticancer drug development. Collaboration to discover novel lung cancer targets using AI-based PDO platform and develop targeted anticancer drugs using BCChem's low-molecular weight synthesis technology.

6Syntec Bio
Strategic tierMajorTypeStrategic or Co-development Partner
Description

MOU with AI drug development company Syntec Bio for building an organoid-based AI drug development platform and developing novel targeted anticancer drugs. Combines PDO-based drug response evaluation with Syntec's AI candidate substance discovery platform.

gradiantbio.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research cooperation agreement with US mRNA therapy developer Strand Therapeutics for next-generation mRNA therapy development. Using organoid and immune cell co-culture platform to verify mRNA therapy efficacy for solid tumor treatment.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Joint research agreement with AI drug development company Dr. Noah Biotech for rare disease treatment development. Combining PDO platform with AI-based drug development platform (ARK platform) for rare disease drug discovery.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Joint business MOU with preclinical CRO HLB Biostep for patient-derived organoid xenograft (PDOX) model development. Building on-demand PDOX production line using company's PDO banking and HLB Biostep's in vivo testing capabilities.

10Curevus
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Brain organoid related cooperation agreement with KIST research institute company Curevus for neurodegenerative disease research.

gradiantbio.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cooperation for non-small cell lung cancer biomarker discovery using company's PDO platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Equipment donation and MOU for anticancer drug development research. Company donated anaerobic chamber for organoid and microbiome research, and will perform efficacy evaluation of Kangwon National University's anticancer drug candidates.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MOU with Korea University Anam Hospital and Oncomaster for patient-derived organoid establishment and precision medicine commercialization. Building PDO system for bladder and lung cancer patients for personalized medical services.

14Oncomaster
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Precision medicine AI company collaborating with company and Korea University Anam Hospital for developing clinical decision support system (CDSS) based on clinical and genomic information for personalized treatment recommendations.

gradiantbio.com
15HUB (Hubrecht Organoid Technology)
Strategic tierCoreTypeTechnology or Integration
Description

Licensing agreement for organoid technology and technology transfer from Netherlands-based HUB, first such agreement in Korea. Provides access to world-recognized organoid culture methodology pioneered by Dr. Sato Toshiro.

gradiantbio.com
16Dr. Sato Toshiro
Strategic tierCoreTypeOthers
Description

World pioneer in organoid technology, first to successfully culture intestinal organoids in 2009, recruited as scientific advisory board member to enhance organoid culture technology and strengthen intellectual property.

gradiantbio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Crown Bioscience operates one of the largest commercial PDX and patient-derived model biobanks for oncology drug discovery and efficacy evaluation, directly competing with Gradient's PDO banking and efficacy-evaluation services for global pharma.

TypeBroad incumbent
Description

Charles River is a global CRO offering preclinical oncology, organoid, and biomarker services; it competes for the same pharma R&D budgets as Gradient's efficacy-evaluation and biomarker-discovery offerings, though as part of a much broader services portfolio.

TypeDirect peer
Description

XtalPi combines AI-driven computational chemistry with automated drug discovery platforms and is a named Gradient collaboration partner; both target AI-enabled small-molecule and biologic discovery for global pharma.

TypeEmerging player
Description

Recursion uses AI and high-throughput biology for drug discovery; comparable as a tech-first platform pursuing AI-driven target ID, though it relies more on cell-based imaging than organoid biology.

TypeEmerging player
Description

Insitro applies ML to biology for drug discovery, including iPSC-derived disease models; comparable in the AI + human-relevant model intersection, though it focuses more on iPSC and genomics than PDO oncology banking.

TypeEmerging player
Description

Synlogic develops engineered microbial and synthetic biology therapeutics with a platform model; partial overlap in the organoid/biology-platform narrative, but more focused on therapeutic development than preclinical services.

7Tempus AI
TypeBroad incumbent
Description

Tempus builds a large multimodal clinical and genomic data library used for AI-driven precision medicine and biomarker discovery; comparable in the data + AI layer behind Gradient's biomarker and target discovery work.

TypeOthers
Description

Personalis provides genomic sequencing and analytics for clinical and translational research; comparable as a genomics data partner/adjacent in precision oncology workflows involving PDO response and genomic integration.

TypeEmerging player
Description

CytoReason applies AI to proprietary human disease models and omics data for pharma drug discovery; comparable as an AI-driven model-based discovery platform serving global pharma, though focused on computational immune/inflammation models.

10Hubrecht Organoid Technology (HUB)
TypeOthers
Description

HUB is the licensor of Gradient's core organoid culture IP and the foundational player in the organoid technology space; an enabling/ecosystem peer rather than a direct competitor in services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gradient Bioconvergence

Drug Discovery Servicesgradiantbio.com

Gradient Bioconvergence firmographics

Firmographics
Name
Gradient Bioconvergence
Legal name
Gradiant Bioconvergence
Website
https://gradiantbio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Gradient Bioconvergence industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Patient-derived organoids
  • Cancer drug discovery
  • AI target discovery
  • Biomarker identification
  • Organoid banking

Where Gradient Bioconvergence is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Gradient Bioconvergence business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Efficacy Evaluation Services: Contract service providing drug efficacy evaluation using proprietary PDO platforms for pharmaceutical and biotech companies.
  2. Biomarker Discovery Services: AI-based biomarker discovery services for drug response prediction and patient stratification.
  3. Target Discovery Services: Novel anticancer target identification and validation services using PDO and AI platforms.
  4. Licensing Royalties: Technology licensing including decellularized scaffold patents and organoid culture technology to other biotech companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Gradient Bioconvergence product offering

Product offering

Core offering

Gradient Bioconvergence develops patient-derived organoids (PDOs) for cancer research and drug development. The company operates Asia's largest PDO banking system with approximately 1,000 organoid types paired with NGS genomic and clinical data, and combines this with proprietary AI algorithms to deliver drug efficacy evaluation, AI-driven anticancer target discovery, biomarker identification, and iPSC-derived organoid research services to pharmaceutical and biotech clients. It also advances its own drug candidate GBC-11004, a third-generation kinase inhibitor for EGFR-resistant NSCLC.

Product overview

Gradient Bioconvergence operates a platform-plus-services model centered on patient-derived organoid (PDO) technology for drug discovery. The core offerings include PDO Banking (Asia's largest organoid bank with ~1,000 species paired with genomic and clinical data), the AI-Driven Target Discovery platform (combining PDO data with proprietary AI algorithms for target identification), iPSC-Derived Organoid Research services for brain disease modeling, Biomaterials for optimized organoid culture, an Immunotherapy Screening Platform using co-culture systems, and the proprietary drug candidate GBC-11004 (a kinase inhibitor for resistant NSCLC). The company licenses HUB organoid technology and employs CRISPR-based validation alongside its AI capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • PDO Banking Asia's largest Patient-Derived Organoid banking service with approximately 1,000 organoid species, each paired with patient clinical information and genomic data (NGS), used by pharmaceutical and biotech clients for drug efficacy evaluation and novel target discovery.
  • AI-Driven Target Discovery AI-driven anticancer target discovery service that combines PDO big data with proprietary AI algorithms to identify high-confidence targets, validated through PDO-based CRISPR systems, for pharmaceutical and biotech partners.
  • iPSC-Derived Organoid Research Customized research services using human induced pluripotent stem cell (hiPSC)-derived brain organoids for degenerative brain disease research, including co-culture models with microglia, for pharmaceutical and academic clients.
  • Biomaterials Decellularized scaffold and culture materials optimized for organoid culture, enabling 3D culture and tissue environment simulation for organoid development, supplied to research and biotech customers.
  • Immunotherapy Screening Platform Co-culture service combining patient-derived organoids with autologous immune cells for immunotherapy efficacy verification, enabling personalized cancer treatment screening for pharmaceutical and biotech clients.
  • GBC-11004 A proprietary novel 3rd generation kinase inhibitor drug candidate targeting EGFR inhibitor-resistant non-small cell lung cancer (NSCLC), being developed by Gradient Bioconvergence for global licensing partnerships.

Quantifiable outcome

  • Drug development timeline reduction from over 10 years to 1-2 years with AI-based target discovery and PDO validation
  • +3 more outcomes

Companies that use Gradient Bioconvergence

Customer profile

Segments3 records

Ideal customer profiles3 records

Gradient Bioconvergence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Gradient Bioconvergence partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core, major and minor.

  • Chonnam National University Hwasun HospitalcoreStrategic or Co-development Partner · 8 December 2025MOU with Chonnam National University Hwasun Hospital for anticancer drug response prediction and cancer organoid bank construction. The collaboration integrates patient-based clinical information with organoid analysis data to improve anticancer drug response prediction accuracy.
  • OmicInsightcoreStrategic or Co-development Partner · 29 October 2025Strategic partnership with US Silicon Valley biotech company OmicInsight to integrate patient-derived organoid (PDO) platforms with spatial omics analysis technology for precision medicine research. The collaboration aims to enable deeper insight into tissue architecture, disease progression, and therapeutic response for drug discovery, precision medicine, and regenerative medicine.
  • Dong-A STcoreStrategic or Co-development Partner · 26 August 2025Joint research agreement with Korean pharmaceutical company Dong-A ST for AI-based new drug development targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders. Leverages organoid analysis, genomic big data, and automated drug discovery platforms to reduce development timelines from over 10 years to 1-2 years and cut costs by 15-30 percent.
  • Yonsei Medical CentercoreStrategic or Co-development PartnerJoint research contract for PDO co-culture and immunotherapy screening platform development with Yonsei Medical Center. Expanding collaboration from lung cancer to pancreatic cancer and ovarian cancer organoid research.
  • BCChemmajorStrategic or Co-development PartnerMOU with BCChem for first-in-class anticancer drug development. Collaboration to discover novel lung cancer targets using AI-based PDO platform and develop targeted anticancer drugs using BCChem's low-molecular weight synthesis technology.
  • Syntec BiomajorStrategic or Co-development PartnerMOU with AI drug development company Syntec Bio for building an organoid-based AI drug development platform and developing novel targeted anticancer drugs. Combines PDO-based drug response evaluation with Syntec's AI candidate substance discovery platform.
  • Strand TherapeuticsmajorStrategic or Co-development PartnerResearch cooperation agreement with US mRNA therapy developer Strand Therapeutics for next-generation mRNA therapy development. Using organoid and immune cell co-culture platform to verify mRNA therapy efficacy for solid tumor treatment.
  • Dr. Noah BiotechmajorStrategic or Co-development PartnerJoint research agreement with AI drug development company Dr. Noah Biotech for rare disease treatment development. Combining PDO platform with AI-based drug development platform (ARK platform) for rare disease drug discovery.
  • HLB BiostepmajorStrategic or Co-development PartnerJoint business MOU with preclinical CRO HLB Biostep for patient-derived organoid xenograft (PDOX) model development. Building on-demand PDOX production line using company's PDO banking and HLB Biostep's in vivo testing capabilities.
  • CurevusminorStrategic or Co-development PartnerBrain organoid related cooperation agreement with KIST research institute company Curevus for neurodegenerative disease research.
  • Medilife ScienceminorStrategic or Co-development PartnerCooperation for non-small cell lung cancer biomarker discovery using company's PDO platform.
  • Kangwon National UniversityminorStrategic or Co-development PartnerEquipment donation and MOU for anticancer drug development research. Company donated anaerobic chamber for organoid and microbiome research, and will perform efficacy evaluation of Kangwon National University's anticancer drug candidates.
  • Korea University Anam HospitalcoreStrategic or Co-development PartnerMOU with Korea University Anam Hospital and Oncomaster for patient-derived organoid establishment and precision medicine commercialization. Building PDO system for bladder and lung cancer patients for personalized medical services.
  • OncomasterminorStrategic or Co-development PartnerPrecision medicine AI company collaborating with company and Korea University Anam Hospital for developing clinical decision support system (CDSS) based on clinical and genomic information for personalized treatment recommendations.
  • HUB (Hubrecht Organoid Technology)coreTechnology or IntegrationLicensing agreement for organoid technology and technology transfer from Netherlands-based HUB, first such agreement in Korea. Provides access to world-recognized organoid culture methodology pioneered by Dr. Sato Toshiro.
  • Dr. Sato ToshirocoreOthersWorld pioneer in organoid technology, first to successfully culture intestinal organoids in 2009, recruited as scientific advisory board member to enhance organoid culture technology and strengthen intellectual property.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Gradient Bioconvergence competitors and assessment

Company assessment

Direct peers

  • Crown Bioscience: Crown Bioscience operates one of the largest commercial PDX and patient-derived model biobanks for oncology drug discovery and efficacy evaluation, directly competing with Gradient's PDO banking and efficacy-evaluation services for global pharma.
  • XtalPi: XtalPi combines AI-driven computational chemistry with automated drug discovery platforms and is a named Gradient collaboration partner; both target AI-enabled small-molecule and biologic discovery for global pharma.

Broad incumbents

  • Charles River Laboratories: Charles River is a global CRO offering preclinical oncology, organoid, and biomarker services; it competes for the same pharma R&D budgets as Gradient's efficacy-evaluation and biomarker-discovery offerings, though as part of a much broader services portfolio.
  • Tempus AI: Tempus builds a large multimodal clinical and genomic data library used for AI-driven precision medicine and biomarker discovery; comparable in the data + AI layer behind Gradient's biomarker and target discovery work.

Emerging players

  • Recursion Pharmaceuticals: Recursion uses AI and high-throughput biology for drug discovery; comparable as a tech-first platform pursuing AI-driven target ID, though it relies more on cell-based imaging than organoid biology.
  • Insitro: Insitro applies ML to biology for drug discovery, including iPSC-derived disease models; comparable in the AI + human-relevant model intersection, though it focuses more on iPSC and genomics than PDO oncology banking.
  • Synlogic: Synlogic develops engineered microbial and synthetic biology therapeutics with a platform model; partial overlap in the organoid/biology-platform narrative, but more focused on therapeutic development than preclinical services.
  • CytoReason: CytoReason applies AI to proprietary human disease models and omics data for pharma drug discovery; comparable as an AI-driven model-based discovery platform serving global pharma, though focused on computational immune/inflammation models.

Others

  • Personalis: Personalis provides genomic sequencing and analytics for clinical and translational research; comparable as a genomics data partner/adjacent in precision oncology workflows involving PDO response and genomic integration.
  • Hubrecht Organoid Technology (HUB): HUB is the licensor of Gradient's core organoid culture IP and the foundational player in the organoid technology space; an enabling/ecosystem peer rather than a direct competitor in services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Gradient Bioconvergence social profiles

Digital presence

Gradient Bioconvergence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gradient Bioconvergence leadership team

Management profile

Number of profiles

Profiles1 record

Gradient Bioconvergence funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gradient Bioconvergence M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gradient Bioconvergence

What does Gradient Bioconvergence do?

Gradient Bioconvergence develops patient-derived organoids (PDOs) for cancer research and drug development. The company operates Asia's largest PDO banking system with approximately 1,000 organoid types paired with NGS genomic and clinical data, and combines this with proprietary AI algorithms to deliver drug efficacy evaluation, AI-driven anticancer target discovery, biomarker identification, and iPSC-derived organoid research services to pharmaceutical and biotech clients. It also advances its own drug candidate GBC-11004, a third-generation kinase inhibitor for EGFR-resistant NSCLC.

Is Gradient Bioconvergence a public or private company?

Gradient Bioconvergence is a private company. It is classified as corporate owned and is currently operating.

When was Gradient Bioconvergence founded?

Gradient Bioconvergence was founded in 2017. It employs 1 to 10 people.

Where is Gradient Bioconvergence based?

Gradient Bioconvergence is headquartered in Seoul, South Korea, in the Asia region.

How does Gradient Bioconvergence make money?

Four revenue lines are on record. Drug Efficacy Evaluation Services are the primary driver. The others are biomarker Discovery Services, target Discovery Services and licensing Royalties.

Who are Gradient Bioconvergence's main competitors?

Direct peers on record are Crown Bioscience and XtalPi. Broad incumbents are Charles River Laboratories and Tempus AI. Emerging players are Recursion Pharmaceuticals, Insitro, Synlogic and CytoReason. Others are Personalis and Hubrecht Organoid Technology (HUB).

Does Gradient Bioconvergence have an API?

No public API is recorded for Gradient Bioconvergence.

What industry is Gradient Bioconvergence in?

Gradient Bioconvergence's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
스타트업엔(StartupN)Gradient Bioconvergence and Curiosis join hands to enhance the organoid-based drug evaluation platform.Gradient BioConvergence and Curiosys signed an MOU to combine Gradient's patient-derived organoid drug evaluation platform with Curiosys's live cell imaging system Celloger. The collaboration aims to enable real-time 3D imaging of organoid growth and drug responses, improving data analysis. The companies plan to expand joint research with pharmaceutical and biotech firms.VenturesquareLive organoid drug response, real-time tracking in 3D... collaboration with Gradient and CuriosisGradient Bioconvergence and Curiosis signed an agreement to combine patient-derived organoid drug evaluation with Curiosis's live-cell imaging tool Cellogger. The partnership aims to track organoid growth and drug responses in 3D over time, expanding analysis of Gradient's 1,000 organoid lines. Both companies plan to improve drug efficacy assessment accuracy and expand Curiosis's imaging technology applications.EIN PresswireOmicInsight and Gradiant Bioconvergence Partner to Pioneer Next-Generation Organoid and Spatial Omics IntegrationOmicInsight and Gradiant Bioconvergence announced a strategic partnership to integrate spatial transcriptomics technology with organoid models, advancing research in spatial biology and therapeutics. This collaboration aims to create an accessible platform that can enhance insights into tissue architecture, disease progression, and drug development. The initiative is expected to impact drug discovery, precision medicine, and regenerative medicine by broadening the availability of data-rich models.